Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

Simple item page
dc.contributor.authorIeDEA and ART Cohort Collaborations
dc.contributor.authorAvila, D.
dc.contributor.authorAlthoff, K. N.
dc.contributor.authorMugglin, C.
dc.contributor.authorWools-Kaloustian, K.
dc.contributor.authorKoller, M.
dc.contributor.authorDabis, F.
dc.contributor.authorNash, D.
dc.contributor.authorGsponer, T.
dc.contributor.authorSungkanuparph, S.
dc.contributor.authorMcGowan, Catherine C.
dc.contributor.authorMay, M.
dc.contributor.authorCooper, D.
dc.contributor.authorChimbetete, C.
dc.contributor.authorWolff, Marcelo
dc.contributor.authorCollier, A.
dc.contributor.authorMcManus, H.
dc.contributor.authorDavies, M. A.
dc.contributor.authorCostagliola, D.
dc.contributor.authorCrabtree-Ramirez, Brenda
dc.contributor.authorChaiwarith, R.
dc.contributor.authorCescon, A.
dc.contributor.authorCornell, M.
dc.contributor.authorDiero, L.
dc.contributor.authorPhanuphak, P.
dc.contributor.authorSawadogo, A.
dc.contributor.authorEhmer, J.
dc.contributor.authorEholie, S. P.
dc.contributor.authorLi, P. C.
dc.contributor.authorFox, M. P.
dc.contributor.authorGandhi, N. R.
dc.contributor.authorGonzález, E.
dc.contributor.authorLee, C. K.
dc.contributor.authorHoffmann, C. J.
dc.contributor.authorKambugu, A.
dc.contributor.authorKeiser, O.
dc.contributor.authorDitangco, R.
dc.contributor.authorProzesky, H.
dc.contributor.authorLampe, F.
dc.contributor.authorKumarasamy, N.
dc.contributor.authorKitahata, M.
dc.contributor.authorLugina, E.
dc.contributor.authorLyamuya, R.
dc.contributor.authorVonthanak, S.
dc.contributor.authorFink, Valeria
dc.contributor.authord'Arminio Monforte, A.
dc.contributor.authorLuz, P. M.
dc.contributor.authorChen, Y. M.
dc.contributor.authorMinga, A.
dc.contributor.authorCasabona, J.
dc.contributor.authorMwango, A.
dc.contributor.authorChoi, J. Y.
dc.contributor.authorNewell, M. L.
dc.contributor.authorBukusi, E. A.
dc.contributor.authorNgonyani, K.
dc.contributor.authorMerati, T. P.
dc.contributor.authorOtieno, J.
dc.contributor.authorBosco, M. B.
dc.contributor.authorPhiri, S.
dc.contributor.authorNg, O. T.
dc.contributor.authorAnastos, Kathryn
dc.contributor.authorRockstroh, J.
dc.contributor.authorSantos, I.
dc.contributor.authorOka, S.
dc.contributor.authorSomi, G.
dc.contributor.authorStephan, C.
dc.contributor.authorTeira, R.
dc.contributor.authorWabwire, D.
dc.contributor.authorWandeler, G.
dc.contributor.authorBoulle, A.
dc.contributor.authorReiss, Peter
dc.contributor.authorWood, R.
dc.contributor.authorChi, B. H.
dc.contributor.authorWilliams, C.
dc.contributor.authorSterne, J. A.
dc.contributor.authorEgger, M.
dc.date.accessioned2024-05-23T15:24:12Z
dc.date.available2024-05-23T15:24:12Z
dc.date.issued2014-1
dc.description.abstractTo describe the CD4 cell count at the start of combination antiretroviral therapy (cART) in low-income (LIC), lower middle-income (LMIC), upper middle-income (UMIC), and high-income (HIC) countries. Methods: Patients aged 16 years or older starting cART in a clinic participating in a multicohort collaboration spanning 6 continents (International epidemiological Databases to Evaluate AIDS and ART Cohort Collaboration) were eligible. Multilevel linear regression models were adjusted for age, gender, and calendar year; missing CD4 counts were imputed. Results: In total, 379,865 patients from 9 LIC, 4 LMIC, 4 UMIC, and 6 HIC were included. In LIC, the median CD4 cell count at cART initiation increased by 83% from 80 to 145 cells/mL between 2002 and 2009. Corresponding increases in LMIC, UMIC, and HIC were from 87 to 155 cells/mL (76% increase), 88 to 135 cells/mL (53%), and 209 to 274 cells/mL (31%). In 2009, compared with LIC, median counts were 13 cells/mL [95% confidence interval (CI): 256 to +30] lower in LMIC, 22 cells/mL (262 to +18) lower in UMIC, and 112 cells/mL (+75 to +149) higher in HIC. They were 23 cells/mL (95% CI: +18 to +28 cells/mL) higher in women than men. Median counts were 88 cells/mL (95% CI: +35 to +141 cells/mL) higher in countries with an estimated national cART coverage .80%, compared with countries with ,40% coverage. Conclusions: Median CD4 cell counts at the start of cART increased 2000–2009 but remained below 200 cells/mL in LIC and MIC and below 300 cells/mL in HIC. Earlier start of cART will require substantial efforts and resources globally.
dc.identifier.citationIeDEA and ART Cohort Collaborations, Avila, D., Althoff, K. N., Mugglin, C., Wools-Kaloustian, K., Koller, M., ... & Egger, M. (2014). Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr, 65(1), e8-16. doi: 10.1097/QAI.0b013e3182a39979.
dc.identifier.otherdoi: 10.1097/QAI.0b013e3182a39979
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1065
dc.relation.ispartofseriesJ Acquir Immune Defic Syndr, 65(1)
dc.subjectAntiretroviral therapy
dc.subjectGlobal health disparities
dc.subjectImmunodeficiency onset
dc.titleImmunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
112_2013_Egger_  Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries..pdf
Size:
497.6 KB
Format:
Adobe Portable Document Format
Download

Collections

Articulos científicos